Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CEMI NASDAQ:ENLV NASDAQ:ORGS NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEMIChembio Diagnostics$0.46$0.43$0.19▼$1.24$16.71M1.85661,416 shs351,642 shsENLVEnlivex Therapeutics$1.34+3.1%$1.05$0.81▼$1.76$30.75M0.79131,847 shs241,459 shsORGSOrgenesis$1.30-1.8%$1.85$0.87▼$10.80$6.24M0.478,295 shs13,828 shsTRDAEntrada Therapeutics$6.76-10.7%$7.73$6.57▼$21.79$287.30M-0.11135,180 shs153,003 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEMIChembio Diagnostics0.00%0.00%0.00%0.00%0.00%ENLVEnlivex Therapeutics+10.17%+15.04%+38.30%+42.86%-4.41%ORGSOrgenesis-6.17%-13.46%-41.67%-27.25%+132,399,900.00%TRDAEntrada Therapeutics+5.73%+4.13%-6.66%-3.57%-51.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCEMIChembio DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AENLVEnlivex Therapeutics3.1495 of 5 stars3.75.00.00.00.00.80.6ORGSOrgenesis1.8183 of 5 stars0.05.00.04.40.00.00.0TRDAEntrada Therapeutics3.5755 of 5 stars3.62.00.00.02.72.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEMIChembio Diagnostics 0.00N/AN/AN/AENLVEnlivex Therapeutics 3.33Buy$10.00646.27% UpsideORGSOrgenesis 0.00N/AN/AN/ATRDAEntrada Therapeutics 3.25Buy$25.67279.68% UpsideCurrent Analyst Ratings BreakdownLatest ORGS, ENLV, CEMI, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025TRDAEntrada TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEMIChembio Diagnostics$48.34M0.35N/AN/A$0.48 per share0.95ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AORGSOrgenesis$662K9.42N/AN/A($6.58) per share-0.20TRDAEntrada Therapeutics$172.22M1.49$1.42 per share4.77$11.46 per share0.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEMIChembio Diagnostics-$23.29M-$1.20N/A∞N/A-47.03%-113.57%-38.22%N/AENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)TRDAEntrada Therapeutics$65.63M$0.818.35N/AN/A14.39%5.84%4.61%8/12/2025 (Estimated)Latest ORGS, ENLV, CEMI, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/8/2025Q1 2025TRDAEntrada Therapeutics-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCEMIChembio DiagnosticsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEMIChembio DiagnosticsN/A1.231.04ENLVEnlivex TherapeuticsN/A7.207.20ORGSOrgenesisN/A0.070.07TRDAEntrada TherapeuticsN/A21.8821.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEMIChembio Diagnostics8.65%ENLVEnlivex Therapeutics1.02%ORGSOrgenesis22.56%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipCEMIChembio Diagnostics3.30%ENLVEnlivex Therapeutics12.28%ORGSOrgenesis5.66%TRDAEntrada Therapeutics8.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEMIChembio Diagnostics33736.73 million35.51 millionNot OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableORGSOrgenesis1504.80 million4.53 millionNo DataTRDAEntrada Therapeutics11037.95 million34.88 millionOptionableORGS, ENLV, CEMI, and TRDA HeadlinesRecent News About These CompaniesEntrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% - Should You Sell?July 8 at 3:33 AM | marketbeat.comEntrada Therapeutics (TRDA) 10% owners sell $866k in stockJuly 3, 2025 | investing.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 SharesJuly 2, 2025 | insidertrades.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 75,000 SharesJuly 1, 2025 | marketbeat.comInsider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,422 Shares of StockJuly 1, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 18,578 SharesJuly 1, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 19,265 SharesJuly 1, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar Sells 25,000 SharesJuly 1, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 55,735 SharesJuly 1, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Upgraded to "Hold" at Wall Street ZenJune 27, 2025 | marketbeat.comWall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to SellJune 14, 2025 | marketbeat.comMillennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)June 12, 2025 | marketbeat.comEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29, 2025 | morningstar.comMEntrada Therapeutics to start DMD trial in Q3 2025May 29, 2025 | investing.comEntrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025May 29, 2025 | nasdaq.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMay 28, 2025 | globenewswire.comAnalysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest ResultsMay 11, 2025 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comEntrada Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORGS, ENLV, CEMI, and TRDA Company DescriptionsChembio Diagnostics NASDAQ:CEMIChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Enlivex Therapeutics NASDAQ:ENLV$1.34 +0.04 (+3.08%) Closing price 03:59 PM EasternExtended Trading$1.35 +0.01 (+0.75%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Orgenesis NASDAQ:ORGS$1.30 -0.02 (-1.81%) As of 03:59 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Entrada Therapeutics NASDAQ:TRDA$6.76 -0.81 (-10.70%) Closing price 04:00 PM EasternExtended Trading$6.80 +0.04 (+0.67%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
